ReNerve (ASX:RNV)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on ReNerve.
RELATED STOCKHEAD STORIES
Break it Down: ReNerve enters high growth Indian market
Study shows ReNerve’s NervAlign offers less post-op nerve-repair pain, more relief
ReNerve scores marketing approval for nerve repair product in Thailand
Lunch Wrap: ASX plunges as momentum trade unwinds; Polynovo rocked by bullying allegations
ReNerve revenue shoots up 167pc in first half year result since IPO
ReNerve inks Mexican deal for nerve repair product NervAlign
ASX Quarterly Health Wrap: EZZ hits an ace, ReNerve’s first quarterly since IPO
ReNerve inks Middle East distribution deal for nerve repair product NervAlign
Break it Down: ReNerve’s exclusive Middle East move
Health Check: The robots are taking over biotech stock selection
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
ReNerve inks deal to expand nerve-repair product in Hong Kong and Macau
Health Check: No sign of frayed nerves as Orthocell girds for US approval
